Skip to main content Back to Top
Advertisement

4/25/2017

Hydroxyamphetamine Hydrobromide and Tropicamide Ophthalmic Solution

Reason for the Shortage

    • Akorn had Paremyd on shortage due to manufacturing delays.
    • No clinical trial data were found to support the use of Paremyd in the diagnosis of Horner Syndrome.

Available Products

    • Paremyd ophthalmic solution, Akorn, 1% hydroxyamphetamine hydrobromide and 0.25% tropicamide, 15 mL bottle, 1 count, NDC 17478-0704-12

Estimated Resupply Dates

    • Akorn has Paremyd ophthalmic solution available.

Updated

Updated April 25, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 13, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT